plozasiran
Nov 28, 2025
Arrowhead Hits the Mark in FCS Treatment with REDEMPLO Approval—Now Comes the Ionis Challenge
Arrowhead Pharmaceuticals has reached a transformational milestone with the FDA’s approval of REDEMPLO (plozasiran) on November 18, 2025—marking the company’s first FDA-approved medicine and the first-ever FDA-approved siRNA therapeutic for familial chylomicronemia syndrome (FCS) treatment. This historic approval r...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
